Jaguar Health, Inc. (JAGX) - Dilution Analysis

10-Q filing | 0.6M shares outstanding

10-K filing | 13.0M shares outstanding

8-K filing: Jaguar Health, Inc. issued 361,271 shares of common stock to Streeterville Capital, LLC in exchange for 25 shares of Series M Preferred Stock.

S-3 filing: This prospectus relates to the resale of up to 2,621,852 shares of Jaguar Health, Inc. voting common stock by the Selling Stockholders listed in this prospectus.

10-Q filing | 2.2M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 1,409,732 shares of Jaguar Health, Inc. voting common stock by the Selling Stockholders.

S-3 filing: This prospectus relates to the resale of up to 507,390 shares of Jaguar Health, Inc. voting common stock issuable upon the exercise of common warrants and placement agent warrants.

10-Q filing | 0.6M shares outstanding

S-3/A filing: This prospectus relates to the resale of up to 1,291,882 shares of Jaguar Health, Inc. voting common stock by the Selling Stockholders listed in this prospectus.

S-3 filing: This prospectus relates to the resale of up to 1,291,882 shares of Jaguar Health, Inc. voting common stock by the Selling Stockholders listed in this prospectus.

10-K filing | 0.7M shares outstanding

8-K filing: Jaguar Health, Inc. entered into securities purchase agreements for a private placement of $3.4 million in convertible promissory notes and warrants, with the offering expected to close on or about March 27, 2025. ($3.94M proceeds)

8-K filing: Stock split 1-for-25 | Outstanding: 11,798,288 → 471,931

10-Q filing | 11.8M shares outstanding

10-Q filing | 1.2M shares outstanding

8-K filing: Jaguar Health, Inc. issued 455,000 shares of common stock in exchange for a $1,851,850 reduction in the outstanding balance of a royalty interest. ($1.85M proceeds)

8-K filing: Jaguar Health, Inc. issued 393,700 shares of common stock in exchange for a $1,500,000 reduction in the outstanding balance of a royalty interest. ($1.5M proceeds)

8-K filing | Stock split 1-for-60 | Outstanding: 73,413,248 → 1,223,554

10-Q filing | 73.4M shares outstanding

S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, warrants, subscription rights, and units up to a total public offering price of $75,000,000.

10-K filing | 0.0M shares outstanding

8-K filing: Jaguar Health, Inc. issued 16,666,666 shares of common stock at $0.12 per share for gross proceeds of approximately $2 million to Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S., and issued 8,333,333 shares of common stock to Streeterville Capital, LLC in exchange for 40 shares of Series J Perpetual Preferred Stock based on an effective exchange price of $0.12 per share of common stock. ($2.0M proceeds)

8-K filing: Jaguar Health, Inc. issued 179.3822 shares of Series J Preferred Stock to Streeterville Capital, LLC on March 1, 2024, and subsequently issued 10,000,000 shares of common stock to Streeterville in exchange for 40 shares of Series J Perpetual Preferred Stock on March 5, 2024.

8-K filing: Jaguar Health, Inc. completed an exchange of PIPE Warrants for 18,837,500 shares of common stock and issued 179.3822 shares of Series J Preferred Stock to Streeterville Capital, LLC in exchange for the surrender of a royalty interest.

10-Q filing | 2.2M shares outstanding

8-K filing: Jaguar Health entered into amendments to royalty interests with Iliad Research and Trading, Uptown Capital, and Streeterville Capital, issued warrants to purchase common stock to these investors, and issued Series I Convertible Preferred Stock to Uptown in exchange for a reduction in the outstanding balance of a royalty interest. ($1.5M proceeds)

10-Q filing | 2.2M shares outstanding

8-K filing: Jaguar Health, Inc. issued 32 shares of Series H Convertible Preferred Stock to Uptown Capital, LLC and 73 shares of Series H Convertible Preferred Stock to Streeterville Capital, LLC in exchange for reductions in outstanding royalty interests.

10-Q filing | 2.2M shares outstanding

8-K filing: Jaguar Health, Inc. entered into a Securities Purchase Agreement to issue Series G Convertible Preferred Stock and warrants for approximately $1.86 million, with the private placement expected to close on May 10, 2023. ($1.86M proceeds)

10-K filing | 2.1M shares outstanding

8-K filing: Stock split 1-for-75 | Outstanding: 48,352,527 → 644,700

8-K filing: The company's board of directors may effect a reverse stock split of the Company's issued and outstanding Common Stock at a ratio of not less than 1-for-3 and not greater than 1-for-75.

10-Q filing | 48.4M shares outstanding

8-K filing: Jaguar Health issued Series E Preferred Shares to SynWorld Technologies Corporation, as outlined in the Securities Purchase Agreement. Ten shares of Series E Preferred Stock was authorized at an original issue price of $10.00 per share.

10-Q filing | 48.4M shares outstanding

8-K filing: Jaguar Health issued 11,500,000 shares of common stock in exchange for a $3,450,000 reduction in royalty interest and issued 17,054,174 shares under an At The Market Offering Agreement for gross proceeds of $5,104,368. ($5.1M proceeds)

10-Q filing | 44.7M shares outstanding

8-K filing: Jaguar Health, Inc. issued 2,000,000 shares of common stock in exchange for an $828,400 reduction in royalty interest and 1,850,000 shares of common stock in exchange for a $747,215 reduction in royalty interest. ($1.58M proceeds)

10-K filing | 2.1M shares outstanding

8-K filing: Jaguar Health, Inc. issued 2,425,000 shares of common stock in exchange for a $1,130,292.50 reduction in the outstanding balance of a royalty interest. ($1.13M proceeds)

8-K filing: Jaguar Health, Inc. issued 2,375,000 shares of common stock in exchange for a $1,733,750 reduction in the outstanding balance of a royalty interest. ($1.73M proceeds)

S-3 filing: This is an S-3 filing for a shelf offering of common stock, preferred stock, warrants and subscription rights up to $75,000,000.

10-Q filing | 2.1M shares outstanding

8-K filing: Jaguar Health, Inc. sold 309,242 unregistered shares of common stock at $2.51 per share for gross proceeds of $776,197 in a private placement. ($0.78M proceeds)

8-K filing: Stock split 1-for-3 | Outstanding: 2,120,786 → 706,221

10-Q filing | 2.1M shares outstanding

S-3 filing: This is an S-3 filing registering the offering of up to 100,000 shares of common stock by the selling stockholder.

10-Q filing | 137.3M shares outstanding

8-K filing: Jaguar Health, Inc. entered into a securities purchase agreement to issue and sell 7,647,000 shares of common stock in a registered public offering for gross proceeds of $10,782,270 before deducting fees and expenses, with the offering expected to close on May 3, 2021. ($10.78M proceeds)

8-K filing: Jaguar Health, Inc. amended its equity line of credit with Oasis Capital, increasing the purchase price and threshold price, and issued a warrant for 100,000 shares of common stock to Oasis Capital.

10-K filing | 127.9M shares outstanding

8-K filing: Jaguar Health entered into a securities purchase agreement to issue and sell 4,437,870 shares of common stock at $3.38 per share in a registered public offering, for gross proceeds of approximately $15 million. ($15.0M proceeds)

8-K filing: Jaguar Health, Inc. issued 2,663,606 shares of its common stock in exchange for a reduction in the outstanding balance of secured promissory notes. ($2.84M proceeds)

8-K filing: Jaguar Health, Inc. issued 11,628,787 shares of Common Stock from December 4, 2020, through December 18, 2020, at an effective market price per share, including 6,060,606 shares on December 15, 2020, and 5,568,181 shares on December 16, 2020, to holders of Series D Perpetual Preferred Stock in exchange for 250,000 and 245,000 shares of Preferred Stock respectively.

8-K filing: Jaguar Health, Inc. issued 7,443,166 shares of Common Stock from October 7, 2020 through November 19, 2020, including issuances to a royalty interest holder and noteholders in exchange for cancellation of a royalty interest and reduction of outstanding balances on secured promissory notes. ($1.2M proceeds)

10-Q filing | 69.4M shares outstanding

8-K filing: Jaguar Health, Inc. entered into a royalty interest purchase agreement with Iliad Research and Trading, L.P. for $6,000,000 and an exchange agreement to exchange 285,000 shares of Series C Perpetual Preferred Stock for 250,000 shares of common stock and pre-funded warrants to purchase 7,057,692 shares of common stock.

8-K filing: Jaguar Health, Inc. issued 2,000,000 shares of common stock and pre-funded warrants to purchase 6,218,954 shares of common stock to Atlas Sciences, LLC as settlement for a trial delay fee. ($2.52M proceeds)

8-K filing: Jaguar Health, Inc. issued 1,333,333 shares of its common stock to PoC Capital, LLC as consideration for PoC's assumption of $399,999.90 in payment obligations of Napo Pharmaceuticals under a service order with Integrium, LLC. ($0.4M proceeds)

8-K filing: Jaguar Health, Inc. issued 4,761,904 shares of Common Stock between August 13, 2020 and September 25, 2020, including 1,428,571 shares on September 23, 2020 and 3,333,333 shares on September 25, 2020, in exchange for reductions in the outstanding balance of secured promissory notes.

S-3 filing: This S-3 filing relates to the potential offering of common stock, preferred stock, warrants, and subscription rights up to $40,000,000 and an offering of 2,289,474 shares of common stock by a selling stockholder.

8-K filing: Jaguar Health, Inc. issued 842,500 shares of Series C Preferred Stock and 842,500 shares of Series D Preferred Stock to Iliad Research and Trading, L.P. in exchange for 5,524,926 shares of Series A Convertible Participating Preferred Stock and issued 2,289,474 shares of common stock to Sagard Capital Partners Management Corp. for services rendered.

8-K filing: Jaguar Health, Inc. consummated the exchange of 5,524,926 shares of Series A Convertible Participating Preferred Stock for 842,500 shares of Series C Perpetual Preferred Stock and 842,500 shares of Series D Perpetual Preferred Stock, and issued 2,289,474 shares of common stock to Sagard Capital Partners, L.P. on September 1, 2020.

10-Q filing | 40.3M shares outstanding

S-3 filing: This S-3 filing includes information on the offering of common stock, including shares issuable upon exercise of warrants, by selling stockholders. It also mentions the potential issuance of a large number of shares of Common Stock may have a negative effect on the trading price of our Common Stock as well as a dilutive effect.

8-K filing: Jaguar Health entered into warrant exercise inducement letters with certain holders of Series 1, Series 2, and Bridge Warrants, who agreed to exercise warrants to purchase 4,572,040, 4,005,062 and 93,750 shares of common stock, respectively, for $4.25 million in exchange for new Series 3 warrants to purchase up to 8,670,852 shares of common stock. ($12.75M proceeds)

10-Q filing | 18.5M shares outstanding

S-1 filing: This S-1 filing describes a private placement of Series B-2 Preferred Stock issued to Oasis Capital, including pre-funded warrants exercisable for Common Stock, and an exchange agreement where Oasis Capital exchanged warrants for Series B-2 Convertible Preferred Stock.

10-K filing | 15.3M shares outstanding

8-K filing: Jaguar Health, Inc. entered into a private placement agreement to sell 1,714,283 shares of common stock for approximately $720,000, a warrant exercise agreement for 1,250,000 shares at $0.5227 per share for gross proceeds of $653,400, and an equity purchase agreement with Oasis Capital for up to $2.0 million of shares of common stock, issuing 68,807 shares to Oasis Capital as a commitment fee. ($1.37M proceeds)

8-K filing: Jaguar Health, Inc. entered into a warrant exercise agreement with a holder of its Series 2 warrants, who agreed to exercise warrants to purchase 90,940 shares of common stock at a reduced exercise price of $0.605 per share for gross proceeds of approximately $55,000. ($0.06M proceeds)

8-K filing: Jaguar Health, Inc. entered into warrant exercise agreements with a holder to exercise warrants to purchase 458,022 shares of common stock at a reduced exercise price of $0.692 per share for gross proceeds of approximately $317,000. ($0.32M proceeds)

S-1 filing: The company is issuing and selling unregistered shares of common stock and warrants to purchase shares of common stock in a private placement for an aggregate purchase price of approximately $1.5 million. The company intends to use the proceeds from the private placement for working capital and general corporate purposes.